Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 16, 2023; 11(32): 7753-7760
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7753
Appropriate leucine-rich α-2 glycoprotein cut-off value for Japanese patients with ulcerative colitis
Masanao Yamazato, Shunichi Yanai, Tomofumi Oizumi, Makoto Eizuka, Shun Yamada, Yosuke Toya, Noriyuki Uesugi, Tamotsu Sugai, Takayuki Matsumoto
Masanao Yamazato, Shunichi Yanai, Tomofumi Oizumi, Makoto Eizuka, Shun Yamada, Yosuke Toya, Takayuki Matsumoto, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Yahaba 028-3695, Japan
Noriyuki Uesugi, Tamotsu Sugai, Division of Molecular Diagnostic Pathology, Iwate Medical University, Yahaba 028-3695, Japan
Author contributions: Yamazato M, and Yanai S performed the conception and design; Yamazato M, Yanai S, Oizumi T, Eizuka M, Yamada S, Toya Y, Uesugi N, and Sugai T performed the data collection; Yamazato M, and Yanai S contributed to the data analysis and statistical analysis; The first draft of manuscript was written by Yamazato M, and Yanai S; Matsumoto T critically reviewed and revised the manuscript; All authors read and approved the final manuscript for submission.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Iwate Medical University Hospital.
Informed consent statement: Patients were not required to give informed consent as this is a retrospective study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shunichi Yanai, Doctor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, 2-1-1 Idaidori, Yahaba 028-3695, Japan. syanai@iwate-med.ac.jp
Received: May 22, 2023
Peer-review started: May 22, 2023
First decision: August 8, 2023
Revised: August 18, 2023
Accepted: November 2, 2023
Article in press: November 2, 2023
Published online: November 16, 2023
ARTICLE HIGHLIGHTS
Research background

Serum leucine-rich α-2 glycoprotein (LRG) can be used for the assessment of disease activity in ulcerative colitis (UC). However, practical cut-off values of LRG for remission have not been established in patients with UC.

Research motivation

LRG cut-off value for remission will lessen the need for colonoscopy.

Research objectives

To establish cut-off values of LRG for endoscopic and histological remission in UC.

Research methods

We retrospectively analyzed the relationship between LRG and clinical, endoscopic and histologic activities in patients with UC.

Research results

In 30 patients, the correlations between LRG value and Mayo Endoscopic Subscore (MES) or UC Endoscopic Index of Severity (UCEIS) were significant (r = 0.754, P < 0.0001; r = 0.778, P < 0.0001, respectively). Significant correlations were also found between CRP level and MES or UCEIS (r = 0.599, P = 0.0005; r = 0.563, P = 0.0012, respectively); however, the correlation coefficients were higher for LRG value. The LRG cut-off value for predicting endoscopic remission was 13.4 μg/mL for an MES of 0 [area under the curve (AUC): 0.871, 95% confidence interval (CI): 0.744–0.998], and 13.4 μg/mL for a UCEIS of 0 or 1 (AUC: 0.904; 95%CI: 0.792–1.000).

Research conclusions

LRG can be applied to the prediction of endoscopic and histological remission in UC.

Research perspectives

Further prospective studies are deemed to validate our findings.